Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
life sciences
national blog main
national top stories
san francisco blog main
san francisco top stories
4
×
biotech
crispr
crispr-cas9
editas medicine
crispr therapeutics
gene editing
intellia therapeutics
national
advaxis
agios therapeutics
aimmune therapeutics
alder biopharmaceuticals
alexander hardy
alphabet
andrew oxtoby
babies
base editing
boston
boulder/denver blog main
boulder/denver top stories
branden moriarty
breakup
bridge bio pharma
broad institute
broad institute of harvard and mit
brook byers
cancer
cas13
ceo
charles chu
clinical hold
clinical study
combination
What
cas
4
×
crispr
4
×
medicine
big
bio
editas
editing
gene
today
available
based
beam
biosciences
bosley's
bosley’s
bridge
bucks
cancer
cells
ceo
cheaper
crime
defect
departure
develop
diagnostics
drive
edited
editor
exit
expects
faster
fears
flag
founders
genetic
gotten
guardian
guiding
harvard
Language
unset
Current search:
crispr
×
cas
×
" san francisco top stories "
×
@xconomy.com
4 years ago
With $45M, Mammoth Bio Expects Big Things From Tiny CRISPR Cas14
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com
5 years ago
Beam Therapeutics Spotlights CRISPR 2.0 with Precise Gene Editor, $87M